Boca Raton, FL - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the Company has identified 45 published manuscripts detailing independent studies involving the use of its PD2i® nonlinear algorithm to identify a wide variety of medical disorders and conditions. This brings the total number of published manuscripts of studies involving Vicor's PD2i® nonlinear algorithm to 60. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

These independent studies, which are not for FDA-approved indications, include the use of Vicor's PD2i® nonlinear algorithm to:

· predict seizure, transplant rejection, and ventricular fibrillation;
· identify stress, depression, sleep apnea, autoimmune system imbalance, increased neural complexity in schizophrenic patients, impact of ECT therapy on depression, and the effect of estrogen and testosterone on convergent and divergent thinking; and

· locate seizure focus for epileptic surgery.

"While the scientific community recognizes that heart rate variability is a useful measure of the health of many bodily functions, the issue for using heart rate variability as a diagnostic in the clinical setting has been thwarted by accuracy issues. As these independent studies attest, Vicor's PD2i® nonlinear algorithm has successfully demonstrated the ability to accurately measure heart rate variability to predict and identify a variety of medical conditions and disorders. We are excited by the range of human conditions and disorders that can be identified early in their arc and thereby provide physicians with the ability to enhance patient treatment and outcomes. We look forward to continuing clinical studies in a variety of areas - chief among these, sudden cardiac death and head trauma in athletes - to establish the Analyzer™ as a widely used diagnostic in the clinical setting," stated Mr. Fater.

More HCB News